<DOC>
	<DOCNO>NCT02148861</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) subcutaneously administer NNC0148-0287 ( insulin 287 ) subject type 2 diabetes</brief_summary>
	<brief_title>A Trial Investigating Safety , Tolerability , Pharmacokinetics Pharmacodynamics Subcutaneously Administered NNC0148-0287 ( Insulin 287 ) Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Male female , age 18 64 year ( inclusive ) time sign informed consent Females childbearing potential [ surgically sterilize ( i.e . tubal ligation , bilateral oophorectomises hysterectomised ) least 3 month postmenopausal ( i.e . define amenorrhoea least 12 month prior screen document FSH ( folliclestimulating hormone ) level 40 U/L ] Body mass index ( BMI ) 20.0 35.0 kg/m^2 ( inclusive ) Type 2 diabetes mellitus ( diagnose clinically ) least 12 month Known suspected hypersensitivity trial product relate product Receipt investigational medicinal product within 3 month screen Use oral antidiabetic drug ( OADs ) glucagonlike peptide1 ( GLP1 ) receptor agonist ( exenatide , liraglutide ) within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>